Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has ...

Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its target price raised by JPMorgan Chase & Co. from $1,150.00 to $1,200.00 in a report released on Friday morning, Benzinga reports.

JPMorgan lowered the firm’s price target on Regeneron (REGN) to $1,150 from $1,200 and keeps an Overweight rating on the shares. The firm updated estimates following the recent Eylea biosimilar ...

JPMorgan Chase & Co.‘s price target would suggest a potential ... TD Cowen reduced their price target on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy ...

Factory Mutual Insurance Co. dramatically upped its stake in Regeneron Pharmaceuticals by 210.3%, acquiring an additional ...

On Tuesday, Morgan Stanley (NYSE: MS) adjusted its outlook on Regeneron (NASDAQ: REGN) Pharmaceuticals stock, reducing the price target from $1,185.00 to $1,150.00.

Regeneron Pharmaceuticals just got a haircut from Wall Street, with JPMorgan Chase & Co. lowering its price target from $950 ...

On Tuesday, Morgan Stanley (NYSE: MS) adjusted its outlook on Regeneron (NASDAQ: REGN) Pharmaceuticals stock, reducing the price target from $1,185.00 to $1,150.00.Despite the decrease, the firm ...